Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash & Current Investments: 2016-2024

Historic Cash & Current Investments for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $51.9 million.

  • Akebia Therapeutics' Cash & Current Investments rose 389.27% to $166.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $469.0 million, marking a year-over-year increase of 196.02%. This contributed to the annual value of $51.9 million for FY2024, which is 20.84% up from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Cash & Current Investments is $51.9 million, which was up 20.84% from $42.9 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Cash & Current Investments high stood at $228.7 million for FY2020, and its period low was $42.9 million during FY2023.
  • Moreover, its 3-year median value for Cash & Current Investments was $51.9 million (2024), whereas its average is $61.8 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 54.85% in 2020, then plummeted by 52.55% in 2023.
  • MRY analysis of 5 years shows Akebia Therapeutics' Cash & Current Investments stood at $228.7 million in 2020, then plummeted by 34.50% to $149.8 million in 2021, then crashed by 39.61% to $90.5 million in 2022, then crashed by 52.55% to $42.9 million in 2023, then rose by 20.84% to $51.9 million in 2024.
  • Its Cash & Current Investments stands at $51.9 million for FY2024, versus $42.9 million for FY2023 and $90.5 million for FY2022.